New drug SP-624 targets brain waves in depression study

NCT ID NCT06570369

Completed Knowledge-focused Sponsor: Sirtsei Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 trial tested whether the experimental drug SP-624 affects brain electrical activity in 26 people — some healthy, some with major depression. Participants took SP-624 or a placebo daily for two weeks. Researchers used EEG and AI to look for changes in brain networks, and also checked memory and learning in those with depression. The main goal was to see if SP-624 has any measurable effect on the brain, not yet to treat the condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SP-624
What this could lead to: If this early study shows SP-624 changes brain activity in a helpful way, it could point toward a new treatment for depression.
What could go wrong: This is a very small, early Phase 1 trial focused on measuring brain signals, not treating depression. It may show no meaningful effect, and results may not lead to a real treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION HEALTHY MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

Alivation Research

Lincoln, Nebraska, 68526, United States
CenExel CNS

Garden Grove, California, 92845, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.